查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1670274

2025年肺癌诊断与筛检全球市场报告

Lung Cancer Diagnostic And Screening Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 200 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年肺癌诊断和筛检市场规模将强劲成长。到 2029 年，这一数字将成长至 36.9 亿美元，复合年增长率为 9.5%。预测期内的成长可归因于肺癌发生率的上升、对早期发现的日益重视、高风险筛检计画的扩大、向个人化医疗的转变、政府倡议和资金筹措。预测期内的关键趋势包括新筛检方法的出现、生物标记检测的进步、人工智慧 (AI) 的整合、液态切片的采用率不断提高、对早期检测的重视以及低剂量 CT筛检计画的扩展。

预计肺癌盛行率的增加将在短期内推动肺癌诊断和筛检市场的成长。肺癌是一种恶性疾病，其症状包括咳嗽、胸痛和呼吸困难，特征是肺组织中异常细胞不受控制地生长。肺癌的诊断和筛检方法在早期发现中发挥重要作用，并利用开放性切片检查和支气管镜检查等各种测试。根据美国癌症协会的资料，截至 2023 年 1 月，美国报告新增肺癌病例约 238,340 例，死亡病例约 127,070 例。肺癌病例的激增凸显了诊断和筛检措施的重要性，刺激了肺癌诊断和筛检市场的成长。

预计医疗保健支出的增加将进一步推动肺癌诊断和筛检市场的扩张。医疗保健支出包括提供或接受医疗服务、治疗以及医疗保健相关商品和活动的总成本。肺癌诊断和筛检的引入将透过早期发现、降低长期治疗成本和改善患者预后后减少医疗支出。 2022年11月，加拿大卫生资讯研究所（CIHI）预测，加拿大的医疗保健总支出将成长0.8%，从2021年的3,280亿美元达到2022年的3,310亿美元。医疗保健支出增加的趋势是肺癌诊断和筛检市场成长的关键驱动因素。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、新冠疫情、经济復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球肺癌诊断与筛检PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素、限制因素）
  • 最终用途产业分析
  • 全球肺癌诊断与筛检市场：成长率分析
  • 全球肺癌诊断与筛检市场表现：规模与成长，2019-2024
  • 全球肺癌诊断与筛检市场预测：规模与成长，2024-2029 年，2034 年
  • 全球肺癌诊断与筛检总目标市场（TAM）

第六章市场区隔

  • 全球肺癌诊断及筛检市场（依产品、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 装置
  • 耗材及配件
  • 全球肺癌诊断与筛检市场：依检测、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 生物标记检测
  • 影像检查
  • 切片检查
  • 血液检查
  • 其他测试
  • 全球肺癌诊断和筛检市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 非小细胞肺癌
  • 小细胞肺癌
  • 全球肺癌诊断和筛检市场（按最终用户、业绩和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 独立诊断实验室
  • 诊断影像中心
  • 癌症研究所
  • 其他最终用户
  • 全球肺癌诊断和筛检市场，按类型细分：仪器、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • 影像设备
  • 切片检查装置
  • 支气管镜系统
  • 全球肺癌诊断和筛检市场，按类型细分：耗材和配件，实际和预测，2019-2024 年、2024-2029 年、2034 年
  • 切片穿刺针
  • 试剂和测定法
  • 影像造影显影剂
  • 病人准备设备
  • 样本采集套件
  • 实验室用品

第七章 区域和国家分析

  • 全球肺癌诊断与筛检市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球肺癌诊断及筛检市场（依国家/地区划分）、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 肺癌诊断与筛检市场：竞争格局
  • 肺癌诊断与筛检市场：公司简介
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Abbott Laboratories Inc.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • FUJIFILM Corporation
  • Koninklijke Philips NV
  • GE Healthcare Bio Sciences AB
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Qiagen Inc.
  • Myriad Genetic Laboratories Inc.
  • NeoGenomics Laboratories Inc.
  • Canon Medical Systems Corporation
  • OncimmuneHoldings Plc
  • Broncus Medical Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年肺癌诊断与筛检市场：提供新机会的国家
  • 2029年肺癌诊断与筛检市场：细分市场将带来新机会
  • 2029年肺癌诊断与筛检市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r25074

Lung cancer diagnosis and screening involve employing examinations and techniques to detect and identify lung cancer, aiming for early detection and accurate diagnosis to facilitate effective treatment planning. This process is commonly applied in the treatment of squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnostic and screening market size has grown strongly in recent years. It will grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to growth in digital imaging, standardization of screening protocols, public health initiatives against tobacco use, establishment of cancer registries, and advancements in pathology analysis

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing incidence of lung cancer, growing emphasis on early detection, expansion of high-risk screening programs, shift towards personalized medicine, government initiatives and funding. Major trends in the forecast period include emergence of novel screening modalities, advancements in biomarker testing, integration of artificial intelligence (AI), rise in liquid biopsy adoption, focus on early stage detection, and expansion of low-dose CT screening programs.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Key players in the lung cancer diagnostic and screening market are advancing technologies such as lung cancer tests aimed at enhancing early detection, improving diagnostic accuracy, and enabling personalized treatment strategies for patients at high risk of the disease. These lung cancer tests utilize various methods, including imaging, biomarker analysis, and cytological examinations, to identify the presence of lung cancer. For example, in December 2023, Freenome, a biotechnology company based in the United States, introduced PROACT LUNG. This trial represents a significant advancement in lung cancer screening, potentially leading to earlier detection and improved patient outcomes while addressing current shortcomings in screening practices.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Diagnostic And Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer diagnostic and screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer diagnostic and screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instruments; Consumables And Accessories
  • 2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests
  • 3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
  • 4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Instruments: Imaging Devices; Biopsy Devices; Bronchoscopy Systems
  • 2) By Consumables And Accessories: Biopsy Needles; Reagents And Assays; Imaging Contrast Agents; Patient Preparation Equipment; Sample Collection Kits; Laboratory Supplies
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca Plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Lung Cancer Diagnostic And Screening Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Lung Cancer Diagnostic And Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Lung Cancer Diagnostic And Screening Market Growth Rate Analysis
  • 5.4. Global Lung Cancer Diagnostic And Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Lung Cancer Diagnostic And Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Lung Cancer Diagnostic And Screening Total Addressable Market (TAM)

6. Lung Cancer Diagnostic And Screening Market Segmentation

  • 6.1. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments
  • Consumables And Accessories
  • 6.2. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biomarkers Tests
  • Imaging Test
  • Biopsy
  • Blood Test
  • Other Tests
  • 6.3. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • 6.4. Global Lung Cancer Diagnostic And Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Other End-Users
  • 6.5. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging Devices
  • Biopsy Devices
  • Bronchoscopy Systems
  • 6.6. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Consumables And Accessories, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy Needles
  • Reagents And Assays
  • Imaging Contrast Agents
  • Patient Preparation Equipment
  • Sample Collection Kits
  • Laboratory Supplies

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

  • 7.1. Global Lung Cancer Diagnostic And Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Lung Cancer Diagnostic And Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

  • 8.1. Asia-Pacific Lung Cancer Diagnostic And Screening Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Diagnostic And Screening Market

  • 9.1. China Lung Cancer Diagnostic And Screening Market Overview
  • 9.2. China Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Diagnostic And Screening Market

  • 10.1. India Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Diagnostic And Screening Market

  • 11.1. Japan Lung Cancer Diagnostic And Screening Market Overview
  • 11.2. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Diagnostic And Screening Market

  • 12.1. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Diagnostic And Screening Market

  • 13.1. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Diagnostic And Screening Market

  • 14.1. South Korea Lung Cancer Diagnostic And Screening Market Overview
  • 14.2. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Diagnostic And Screening Market

  • 15.1. Western Europe Lung Cancer Diagnostic And Screening Market Overview
  • 15.2. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Diagnostic And Screening Market

  • 16.1. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Diagnostic And Screening Market

  • 17.1. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Diagnostic And Screening Market

  • 18.1. France Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Diagnostic And Screening Market

  • 19.1. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Diagnostic And Screening Market

  • 20.1. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

  • 21.1. Eastern Europe Lung Cancer Diagnostic And Screening Market Overview
  • 21.2. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Diagnostic And Screening Market

  • 22.1. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Diagnostic And Screening Market

  • 23.1. North America Lung Cancer Diagnostic And Screening Market Overview
  • 23.2. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Diagnostic And Screening Market

  • 24.1. USA Lung Cancer Diagnostic And Screening Market Overview
  • 24.2. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Diagnostic And Screening Market

  • 25.1. Canada Lung Cancer Diagnostic And Screening Market Overview
  • 25.2. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Diagnostic And Screening Market

  • 26.1. South America Lung Cancer Diagnostic And Screening Market Overview
  • 26.2. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Diagnostic And Screening Market

  • 27.1. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Diagnostic And Screening Market

  • 28.1. Middle East Lung Cancer Diagnostic And Screening Market Overview
  • 28.2. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Diagnostic And Screening Market

  • 29.1. Africa Lung Cancer Diagnostic And Screening Market Overview
  • 29.2. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

  • 30.1. Lung Cancer Diagnostic And Screening Market Competitive Landscape
  • 30.2. Lung Cancer Diagnostic And Screening Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories Inc.
  • 31.2. Danaher Corporation
  • 31.3. Siemens Healthcare GmbH
  • 31.4. FUJIFILM Corporation
  • 31.5. Koninklijke Philips N.V.
  • 31.6. GE Healthcare Bio Sciences AB
  • 31.7. Quest Diagnostics Incorporated
  • 31.8. Agilent Technologies Inc.
  • 31.9. Illumina Inc.
  • 31.10. Qiagen Inc.
  • 31.11. Myriad Genetic Laboratories Inc.
  • 31.12. NeoGenomics Laboratories Inc.
  • 31.13. Canon Medical Systems Corporation
  • 31.14. OncimmuneHoldings Plc
  • 31.15. Broncus Medical Inc.

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

34. Recent Developments In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market High Potential Countries, Segments and Strategies

  • 35.1 Lung Cancer Diagnostic And Screening Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Lung Cancer Diagnostic And Screening Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Lung Cancer Diagnostic And Screening Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer